Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1884-1890

  Creagan, Edward T ^a   Suman, Vera J ^a   Dalton, Robert J ^a   Pitot, Henry C ^a   Long, Harry J ^a   Veeder, Michael H ^a   Vukov, Allen M ^a   Rowland, Kendrith M ^a   Krook, James E ^a   Michalak, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; GLUCOSE; SODIUM CHLORIDE; TAMOXIFEN; WATER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0033001687     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1884     Document Type: Article

References (19)

1. McClay EF, McClay ME: Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 23:744-753, 1996
2. Hansson J: Systemic therapy of malignant melanoma. Med Oncol 14:73-81, 1997
3. Anderson CM, Buzaid AC, Legha SS: Systemic treatments for advanced cutaneous melanoma. Oncology 9:1149-1168, 1995
4. Philip PA, Flaherty L: Treatment of malignant melanoma with interleukin-2. Semin Oncol 24:S32-S38, 1997 (1 suppl 4)
5. Kirkwood JM, Agarwala SS: Systemic cytotoxic and biologic therapy of melanoma. PPO Updates 7:1-16, 1993
6. Eton O, Talpaz M, Lee KH, et al: Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: Implications for the treatment of patients with metastatic melanoma. Cancer 77:893-899, 1996
7. Punt CJ, van Herpen CM, Jansen RL, et al: Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: A multicentre phase II study. Br J Cancer 76:266-269, 1997
8. Del Prete SA, Maurer LH, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
9. McClay EF, Mastrangelo MJ, Bellet RE, et al: Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 71:465-469, 1987
10. McClay EF, Mastrangelo MJ, Sprandio JD, et al: The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292-1295, 1989
11. Pocock SL, Simon R: Sequential treatment assignment with balancing for prognostic factors in controlled clinical trials. Biometrics 31:103-115, 1975
12. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:547-581, 1958
13. Fisher RA: Statistical methods for research workers. Edinburgh, Scotland, United Kingdom, Oliver and Boyd, 1941
14. Peto R, Peto J: Asymptotically efficient rank invariant procedures (with discussion). J R Stat Soc 135:185-207, 1972
15. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1972
16. Walker SH, Duncan DB: Estimation of the probability of an event as a function of several independent variables. Biometrika 54:167-179, 1967
17. Lattanzi SC, Tosteson T, Chertoff J, et al: Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res 5:365-369, 1995
18. Margolin KA, Liu PY, Flaherty LE, et al: Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol 16:664-669, 1998
19. Rusthoven JJ, Quirt IC, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2083-2090, 1996